Cerivastatin does not prevent oxidative injury of human aortic endothelial cells

Sharif Al-Ruzzeh1, Ilona Schmidt, Koki Nakamura

  • 1Department of Cardiothoracic Surgery, Harefield Hospital, Middlesex UB9 6JH, United Kingdom.

Insights

Cerivastatin, a statin, did not protect human aortic endothelial cells from oxidative stress. This study found no evidence that cerivastatin prevents injury caused by hydrogen peroxide or superoxide anions.

Area of Science:

  • Cardiovascular Research
  • Cell Biology
  • Pharmacology

Background:

  • Statins (HMG-CoA reductase inhibitors) are known for anti-atherogenic properties.
  • Statins' potential to mitigate ischemia-reperfusion injury via antioxidant effects is debated.
  • Oxidative stress plays a role in vascular injury.

Purpose of the Study:

  • To investigate if cerivastatin protects human aortic endothelial cells (HAEC) from oxidative stress-induced injury.
  • To determine if cerivastatin exhibits antioxidant capabilities in vascular endothelial cells.

Main Methods:

  • HAEC were exposed to oxidative stress using hydrogen peroxide or diethylthiocarbamate.
  • Cerivastatin (50 nM-1,000 nM) or N-acetyl-L-cysteine pretreatment was applied.
  • Cell viability (MTT assay) and morphology were assessed.

Main Results:

  • Cerivastatin alone did not affect HAEC viability or morphology.
  • Cerivastatin pretreatment did not protect HAEC against hydrogen peroxide-induced cell death.
  • Neither cerivastatin nor N-acetyl-L-cysteine protected HAEC from diethylthiocarbamate-induced injury.

Conclusions:

  • Cerivastatin does not protect cultured human aortic endothelial cells against oxidative stress.
  • The proposed antioxidant or cytoprotective effects of cerivastatin in this context were not demonstrated.
  • Further research is needed to clarify the role of statins in mitigating oxidative stress-related vascular damage.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...